Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mucin 20, cell surface associated (MUC20)
- Target
- MUC20
- Molecular classification
- Mucin family protein, Glycoprotein, Cell surface-associated protein
01
Overview
Mucin 20, cell surface associated (MUC20) is a high molecular weight glycoprotein and a member of the mucin protein family, widely expressed in epithelial tissues where it contributes to the formation of an insoluble mucous barrier[2][6][7]. The protein exhibits isoforms that localize either to the plasma membrane (shorter isoform) or are secreted (longer isoform), featuring a tandem repeat domain with variability in individual copy number[1]. MUC20 interacts with the MET proto-oncogene (c-Met) at its C-terminus and is involved in the suppression of some downstream MET signaling cascades, linking it to processes such as cell proliferation, signaling modulation, and potentially cancer biology[1][3]. Multiple transcript variants and widespread tissue distribution underscore its physiological and disease significance[4].
- Other names
- Mucin-20KIAA1359UNQ2782/PRO7170MUC-20FLJ14408mucin-20transmembrane mucin MUC20S
02
Mechanism of action
Potential target for modulation of MET signaling pathway in cancer biology[1][3][9].
03
Biological functions
Forms mucous barrier in epithelial tissuesModulates cell signalingSuppresses some downstream MET signaling cascades (via interaction with the MET proto-oncogene)
04
Disease associations
Cancer (notably associated with signaling modulation in certain cancers)Potential role in inflammation and tumor biology
05
Safety considerations
None specifically attributed in clinical settings as of current knowledge; general risks may relate to targeting pathways regulating cell proliferation or mucin expression (speculative)[1].
06
Interacting drugs
None specifically listed or approved as of current knowledge; may be investigated through research settings targeting MET pathway modulation[9].
07
Biomarkers
Antibodies to MUC20 (used in research and immunohistochemistry)[1]May be explored as a biomarker in cancers where MUC20 or MET pathways are implicated (research/NLP inference)
Beyond the preview
Go deeper on Mucin 20, cell surface associated (MUC20).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mucin 20, cell surface associated (MUC20).